

# VICAL INC

## FORM 8-K

(Current report filing)

Filed 08/01/12 for the Period Ending 08/01/12

Address	10390 PACIFIC CENTER COURT
	.
	SAN DIEGO, CA 92121-4340
Telephone	858-646-1100
CIK	0000819050
Symbol	VICL
SIC Code	2836 - Biological Products, Except Diagnostic Substances
Industry	Biotechnology & Drugs
Sector	Healthcare
Fiscal Year	12/31

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## FORM 8-K

### CURRENT REPORT

**Pursuant to Section 13 or 15(d) of  
The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **August 1, 2012**

### **Vical Incorporated**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**000-21088**  
(Commission File Number)

**93-0948554**  
(IRS Employer  
Identification No.)

**10390 Pacific Center Court**  
**San Diego, California**  
(Address of principal executive offices)

**92121-4340**  
(Zip Code)

Registrant's telephone number, including area code: **(858) 646-1100**

**Not Applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 

#### **Item 2.02. Results of Operations and Financial Condition.**

On August 1, 2012, Vical Incorporated issued a press release announcing, among other things, its unaudited financial results for the three months and six months ended June 30, 2012. A copy of the press release is attached as Exhibit 99.1 to this Current Report.

The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.

#### **Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### **Vical Incorporated**

Date: August 1, 2012

By: /s/ JILL M. BROADFOOT

Jill M. Broadfoot

*Senior Vice President, Chief Financial Officer and Secretary*

---

## INDEX TO EXHIBITS

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release issued by Vical Incorporated on August 1, 2012.

## Vical Reports Second Quarter 2012 Financial Results and Progress in Key Development Programs

SAN DIEGO, Aug. 1, 2012 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today reported financial results for the three months and six months ended June 30, 2012. Revenues were \$1.6 million for the second quarter of 2012 compared with \$0.8 million for the second quarter of 2011, reflecting ongoing reimbursements from Astellas Pharma Inc. for costs and expenses related to the development of TransVax™, Vical's therapeutic vaccine designed to control cytomegalovirus (CMV) reactivation in transplant recipients. The net loss was \$7.9 million, or \$0.09 per share, for the second quarter of 2012, compared with \$8.4 million, or \$0.12 per share, for the second quarter of 2011.

Revenues were \$13.0 million for the first half of 2012 compared with \$1.5 million for the first half of 2011. The 2012 revenue includes the recognition of a \$10 million milestone payment from Astellas for progress with TransVax™ which occurred in the first quarter of 2012. The net loss was \$7.6 million, or \$0.09 per share, for the first half of 2012, compared with \$17.1 million, or \$0.24 per share, for the first half of 2011.

Vical had cash and investments of approximately \$97 million at June 30, 2012. The company's net cash uses in the first half of 2012 were consistent with the company's prior guidance for the full year.

Program highlights include:

### Allovetin®

- In the company's Phase 3 registration trial of Allovetin® in patients with metastatic melanoma, data collection for the primary endpoint (response rate at 24 weeks or more after randomization) is completed and independent adjudication is ongoing. The company expects to reach the target number of death events for the secondary endpoint (overall survival) in late 2012, and to release top-line data for both endpoints as soon as practical after that.

### TransVax™ CMV Vaccine

- Astellas is planning to initiate a pivotal, multinational Phase 3 trial of TransVax™ in hematopoietic stem cell transplant (HSCT) recipients in the second half of 2012 and to initiate a Phase 2 trial of TransVax™ for solid organ transplant (SOT) recipients shortly thereafter.

### HSV-2 Vaccine Program

- At the 15th Annual Meeting of the American Society of Gene & Cell Therapy (Philadelphia – May 16-19), Vical presented results from multiple animal studies with the company's Vaxfectin®-formulated plasmid DNA (pDNA) vaccines against herpes simplex virus type 2 (HSV-2) demonstrating proof of concept. Results from the company's completed mouse studies with the HSV-2 vaccines were recently published online in *The Journal of General Virology*. The company is completing preclinical requirements and expects to initiate a Phase 1/2 clinical trial in 2013.

### Conference Call

Vical will conduct a conference call and webcast today, August 1, at noon Eastern Time, to discuss with invited analysts and institutional investors the company's financial results and program updates. The call and webcast are open on a listen-only basis to any interested parties. To listen to the conference call, dial in approximately ten minutes before the scheduled call to (719) 325-2356 (preferred), or (888) 318-7469 (toll-free), and reference confirmation code 3419348. A replay of the call will be available for 48 hours beginning about two hours after the call. To listen to the replay, dial (719) 457-0820 (preferred) or (888) 203-1112 (toll-free) and enter replay passcode 3419348. The call also will be available live and archived through the events page at [www.vical.com](http://www.vical.com). For further information, contact Vical's Investor Relations department by phone at (858) 646-1127 or by e-mail at [ir@vical.com](mailto:ir@vical.com).

### About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at [www.vical.com](http://www.vical.com).

## Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include net cash use guidance, as well as anticipated developments in independent and collaborative programs, including the initiation and completion of clinical trials. Risks and uncertainties include whether Vical or others will continue development of Allovectin<sup>®</sup>, TransVax<sup>™</sup>, the HSV-2 vaccine, or any other independent or collaborative programs; whether Vical will reach the target number of death events for the secondary endpoint (overall survival) and release top-line data from the company's Phase 3 registration trial of Allovectin<sup>®</sup> in patients with metastatic melanoma on the projected timetable, if at all; whether Astellas will initiate the planned HSCT trial of TransVax<sup>™</sup> in the second half of 2012, if at all, and the planned SOT trial of TransVax<sup>™</sup> shortly thereafter, if at all; whether Vical or others will initiate a Phase 1/2 clinical trial of the HSV-2 vaccine in 2013, if at all; whether preclinical results will be predictive of results in human clinical testing; whether Vical will achieve levels of revenues and control expenses to meet its financial projections; whether any product candidates will be shown to be safe and efficacious in clinical trials; the timing of clinical trials; whether Vical or its collaborative partners will seek or gain approval to market any product candidates; and additional risks set forth in the company's filings with the Securities and Exchange Commission. These forward-looking statements represent the company's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements.

## VICAL INCORPORATED

### Selected Condensed Financial Information (Unaudited)

#### Statements of Operations

(in thousands, except per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,	
	2012	2011	2012	2011
Revenues:				
Contract and grant revenue	\$1,364	\$717	\$2,585	\$1,247
License and royalty revenue	201	101	10,440	220
Total revenues	1,565	818	13,025	1,467
Operating expenses:				
Research and development	3,791	4,209	10,219	8,499
Manufacturing and production	2,933	2,606	5,405	5,354
General and administrative	2,778	2,454	5,478	4,782
Total operating expenses	9,502	9,269	21,102	18,635
Loss from operations	(7,937)	(8,451)	(8,077)	(17,168)
Net investment and other income (expense)	69	45	453	68
Net loss	<u>\$(7,868)</u>	<u>\$(8,406)</u>	<u>\$(7,624)</u>	<u>\$(17,100)</u>
Basic and diluted net loss per share	<u>\$(0.09)</u>	<u>\$(0.12)</u>	<u>\$(0.09)</u>	<u>\$(0.24)</u>
Weighted average shares used in computing basic and diluted net loss per share	<u>86,282</u>	<u>71,961</u>	<u>85,412</u>	<u>71,930</u>

#### Balance Sheets

(in thousands)

	June 30, 2012	December 31, 2011
Assets:		
Cash, cash equivalents, and marketable securities, including restricted	\$94,814	\$50,427
Other current assets	3,777	3,130
Total current assets	98,591	53,557
Long-term investments	2,198	5,928
Property and equipment, net	5,873	6,226
Other assets	3,054	3,062
Total assets	<u>\$109,716</u>	<u>\$68,773</u>
Liabilities and stockholders' equity:		
Current liabilities	\$5,064	\$6,461
Long-term liabilities	1,820	1,964

Stockholders' equity	<u>102,832</u>	<u>60,348</u>
Total liabilities and stockholders' equity	<u>\$109,716</u>	<u>\$68,773</u>

CONTACT: Alan R. Engbring  
Executive Director, Investor Relations

Jill M. Broadfoot  
Senior Vice President and Chief Financial Officer

(858) 646-1127  
Website: [www.vical.com](http://www.vical.com)